Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Non Operating Income: 2019-2024

Historic Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $15.8 million.

  • Lyell Immunopharma's Non Operating Income fell 182.05% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 6.51%. This contributed to the annual value of $15.8 million for FY2024, which is 27.35% up from last year.
  • Lyell Immunopharma's Non Operating Income amounted to $15.8 million in FY2024, which was up 27.35% from $12.4 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Non Operating Income peaked at $15.8 million during FY2024, and registered a low of -$35.4 million during FY2021.
  • Its 3-year average for Non Operating Income is $10.7 million, with a median of $12.4 million in 2023.
  • In the last 5 years, Lyell Immunopharma's Non Operating Income tumbled by 574.79% in 2021 and then soared by 214.11% in 2023.
  • Yearly analysis of 5 years shows Lyell Immunopharma's Non Operating Income stood at $7.5 million in 2020, then plummeted by 574.79% to -$35.4 million in 2021, then spiked by 111.12% to $3.9 million in 2022, then soared by 214.11% to $12.4 million in 2023, then increased by 27.35% to $15.8 million in 2024.